Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Epanova (Omefas) in Severe Hypertriglyceridemia.

Next Previous
Trial Profile

Efficacy and Safety of Epanova (Omefas) in Severe Hypertriglyceridemia.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omega-3 carboxylic acids (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms EVOLVE
  • Sponsors AstraZeneca

    • Most Recent Events

    • 06 May 2014 According to an AstraZeneca media release, FDA approval was granted for Epanova based on data that included results from this trial.
    • 09 Jul 2013 Positive results from this trial are included in the NDA submission to the FDA for Epanova for the treatment of patients with very high triglyceride levels, according to an Omthera Pharmaceuticals media release.
    • 09 Nov 2012 Results were presented at the Scientific Sessions of the American Heart Association (AHA).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top